Phase 1/2 Study of Dual-Target CAR-NK Cells in Recurrent Ovarian Cancer

This ongoing Phase 1/2 study investigates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in patients with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. The study employs a 3+3 dose escalation design to establish a recommended Phase 2 dose (RP2D) for each antigen-pair cohort, followed by dose expansion to evaluate efficacy and biomarkers. Tumor expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha), and MUC16 is assessed via immunohistochemistry or flow cytometry, with eligibility requiring expression of at least two targets. Participants are assigned to a dual-target CAR-NK product based on their tumor antigen profile to minimize antigen escape. The primary outcomes include the incidence of dose-limiting toxicities and treatment-emergent adverse events. The study aims to enroll 36 participants, with completion anticipated in 2027. Safety and efficacy data will inform future trials and potential therapeutic strategies for these challenging malignancies.

Imagine facing ovarian cancer that keeps coming back, leaving you feeling out of options. Recurrent ovarian cancer is tough to treat, often resisting standard therapies and leading to a challenging journey for many women. A new clinical trial is exploring a promising approach using dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells, which are specially designed immune cells that can attack cancer. By matching these cells to specific markers found in patients' tumors, the hope is to enhance their effectiveness and reduce the chance of the cancer evading treatment. This study is currently recruiting participants and aims to assess both the safety and early signs of how well this therapy works. While results are still pending, this could mean a new lifeline for women who have exhausted other treatment options. However, it's important to remember that this is still in the early stages, and more research will be needed to fully understand its benefits and risks. For now, this trial represents a beacon of hope in the ongoing fight against ovarian cancer.